USD 0.49
(-2.37%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 6.29 Million USD | -75.5% |
2022 | 25.67 Million USD | -77.44% |
2021 | 113.78 Million USD | -6.77% |
2020 | 122.04 Million USD | -8.08% |
2019 | 132.77 Million USD | 14.18% |
2018 | 116.28 Million USD | 3.76% |
2017 | 112.06 Million USD | 6.39% |
2016 | 105.33 Million USD | 11.26% |
2015 | 94.67 Million USD | 138.11% |
2014 | 39.76 Million USD | 7.83% |
2013 | 36.87 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 12.12 Million USD | -2.51% |
2024 Q1 | 12.43 Million USD | 97.74% |
2023 FY | 6.29 Million USD | -75.5% |
2023 Q3 | 4.95 Million USD | -32.19% |
2023 Q4 | 6.29 Million USD | 26.97% |
2023 Q1 | 12.05 Million USD | -53.06% |
2023 Q2 | 7.3 Million USD | -39.37% |
2022 Q2 | 22.99 Million USD | -79.15% |
2022 Q4 | 25.67 Million USD | 23.61% |
2022 FY | 25.67 Million USD | -77.44% |
2022 Q1 | 110.24 Million USD | -3.11% |
2022 Q3 | 20.76 Million USD | -9.66% |
2021 Q3 | 115.28 Million USD | -0.25% |
2021 Q4 | 113.78 Million USD | -1.3% |
2021 Q2 | 115.57 Million USD | 0.8% |
2021 Q1 | 114.65 Million USD | -6.05% |
2021 FY | 113.78 Million USD | -6.77% |
2020 Q4 | 122.04 Million USD | -1.6% |
2020 FY | 122.04 Million USD | -8.08% |
2020 Q1 | 132.62 Million USD | -0.12% |
2020 Q3 | 124.03 Million USD | -2.74% |
2020 Q2 | 127.53 Million USD | -3.84% |
2019 Q3 | 133.25 Million USD | -0.21% |
2019 Q2 | 133.53 Million USD | 10.05% |
2019 Q1 | 121.33 Million USD | 4.35% |
2019 FY | 132.77 Million USD | 14.18% |
2019 Q4 | 132.77 Million USD | -0.36% |
2018 Q4 | 116.28 Million USD | 0.65% |
2018 FY | 116.28 Million USD | 3.76% |
2018 Q3 | 115.53 Million USD | 1.71% |
2018 Q2 | 113.58 Million USD | 0.79% |
2018 Q1 | 112.69 Million USD | 0.56% |
2017 Q1 | 108.1 Million USD | 2.63% |
2017 Q3 | 113.05 Million USD | 2.95% |
2017 Q4 | 112.06 Million USD | -0.88% |
2017 Q2 | 109.81 Million USD | 1.59% |
2017 FY | 112.06 Million USD | 6.39% |
2016 Q2 | 100.07 Million USD | 2.34% |
2016 Q4 | 105.33 Million USD | 2.53% |
2016 Q3 | 102.72 Million USD | 2.65% |
2016 FY | 105.33 Million USD | 11.26% |
2016 Q1 | 97.78 Million USD | 3.29% |
2015 Q4 | 94.67 Million USD | 3.36% |
2015 Q2 | 30.16 Million USD | -12.57% |
2015 FY | 94.67 Million USD | 138.11% |
2015 Q3 | 91.59 Million USD | 203.6% |
2015 Q1 | 34.5 Million USD | -13.21% |
2014 FY | 39.76 Million USD | 7.83% |
2014 Q4 | 39.76 Million USD | 6.41% |
2014 Q1 | 35.35 Million USD | -4.12% |
2014 Q2 | 44.82 Million USD | 26.79% |
2014 Q3 | 37.36 Million USD | -16.64% |
2013 Q3 | 27.45 Million USD | -21.0% |
2013 Q1 | 31.06 Million USD | 0.0% |
2013 FY | 36.87 Million USD | 0.0% |
2013 Q4 | 36.87 Million USD | 34.29% |
2013 Q2 | 34.75 Million USD | 11.89% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Journey Medical Corporation | 56.49 Million USD | 88.867% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.666% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | 96.162% |
Pacira BioSciences, Inc. | 704.25 Million USD | 99.107% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -2.45% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -2.45% |
SCYNEXIS, Inc. | 55.45 Million USD | 88.656% |
Safety Shot Inc | 3.89 Million USD | -61.612% |
Alpha Teknova, Inc. | 38.55 Million USD | 83.684% |
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.336% |
Bright Green Corporation | 6.43 Million USD | 2.3% |
Dynavax Technologies Corporation | 375.02 Million USD | 98.323% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 99.048% |
Cosmos Health Inc. | 30.25 Million USD | 79.208% |
PainReform Ltd. | 2.69 Million USD | -133.742% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 31.605% |
Embecta Corp. | 2.03 Billion USD | 99.691% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | 95.404% |
Procaps Group, S.A. | 462.06 Million USD | 98.639% |
Theratechnologies Inc. | 98.63 Million USD | 93.623% |
Harrow Health, Inc. | 241.75 Million USD | 97.398% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 28.164% |
Biofrontera Inc. | 23.13 Million USD | 72.816% |
DURECT Corporation | 30.4 Million USD | 79.313% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.71% |
Cronos Group Inc. | 43.73 Million USD | 85.618% |
OptiNose, Inc. | 194.33 Million USD | 96.763% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.23% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | 87.016% |
RedHill Biopharma Ltd. | 20.97 Million USD | 70.016% |
Organogenesis Holdings Inc. | 181.36 Million USD | 96.532% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -66.749% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 88.023% |
Radius Health, Inc. | 804.29 Million USD | 99.218% |
Universe Pharmaceuticals INC | 13.75 Million USD | 54.269% |
ProPhase Labs, Inc. | 42.54 Million USD | 85.215% |
Phibro Animal Health Corporation | 725.54 Million USD | 99.133% |
Procaps Group S.A. | 462.06 Million USD | 98.639% |
Alvotech | 1.88 Billion USD | 99.666% |
TherapeuticsMD, Inc. | 14.02 Million USD | 55.142% |
Viatris Inc. | 27.21 Billion USD | 99.977% |
Rockwell Medical, Inc. | 30.88 Million USD | 79.632% |
Aytu BioPharma, Inc. | 90.37 Million USD | 93.04% |
SIGA Technologies, Inc. | 57.97 Million USD | 89.151% |
Tilray Brands, Inc. | 892.11 Million USD | 99.295% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 97.138% |
Shineco, Inc. | 47.6 Million USD | 86.786% |
PetIQ, Inc. | 645.22 Million USD | 99.025% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -2765.447% |
Incannex Healthcare Limited | 5.83 Million USD | -7.89% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.383% |
Alimera Sciences, Inc. | 107.35 Million USD | 94.141% |
Silver Spike Investment Corp. | 3 Million USD | -108.982% |
Assertio Holdings, Inc. | 148.41 Million USD | 95.762% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -231.757% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | 70.491% |
Clever Leaves Holdings Inc. | 7.02 Million USD | 10.475% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | 25.917% |
Avadel Pharmaceuticals plc | 173.38 Million USD | 96.372% |
Hempacco Co., Inc. | 18.82 Million USD | 66.582% |
Alvotech | 1.88 Billion USD | 99.666% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 96.356% |
Lantheus Holdings, Inc. | 835.25 Million USD | 99.247% |
Currenc Group, Inc. | 177.67 Million USD | 96.46% |
Kamada Ltd. | 109.96 Million USD | 94.28% |
Indivior PLC | 1.95 Billion USD | 99.678% |
Evoke Pharma, Inc. | 9.64 Million USD | 34.806% |
Flora Growth Corp. | 17.22 Million USD | 63.477% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | 25.917% |
Evolus, Inc. | 209.68 Million USD | 97.0% |
HUTCHMED (China) Limited | 536.38 Million USD | 98.827% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.28% |
Akanda Corp. | 12.66 Million USD | 50.351% |